High-Efficiency Bohle Tablet Coater - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

High-Efficiency Bohle Tablet Coater


L.B. Bohle has developed the future of tablet coating, the high-efficiency Bohle Tablet Coater (BTC). The tablet coater reduces processing times up to 35 percent compared to conventional tablet coating systems, yielding significant cost savings and improved campaign efficiency while maintaining cGMP standards.

The BTC provides superior coating uniformity, producing considerably fewer rejects and using less coating material. L.B. Bohle’s patented air flow bed technology eliminates spray drying, thereby reducing waste while lengthening campaigns between cleaning. It also promotes uniform tablet coating with a high-quality, defect-free film coat.

The tablet coater’s elongated coating pan provides a larger tablet spraying surface accommodating up to 10 spray nozzles, which delivers more suspension solution and reduces overall coating time. The BTC’s integrated mixing baffles are double-helix shaped to ensure thorough tablet mixing with gentle handling. The baffle design provides 100-percent tablet discharge, increasing campaign efficiency.

The BTC is ergonomically designed for efficient material handling and is capable of Wash-in-Place (WIP) cleaning. The BTC spray arm and nozzles are mounted on the front door assembly, simplifying inspection and maintenance.

 

The L.B. Bohle Coating products:

  • Bohle Tablet Coater BTC
  • Bohle Film Coater BFC TriPan
  • Bohle Film Coater BFC

Contact:
Tobias Borgers
Head of Marketing
Phone: +49 25 24 - 93 23 0
Fax: +49 25 24 - 93 23 399
Email: t.borgers@lbbohle.de
Web: www.lbbohle.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here